Forbion leads €25m series-A for Azafaros

The round also saw participation from BioMedPartners and BioGeneration Ventures (BGV).

Forbion operating partner Carlo Incerti and managing partner Sander Slootweg join Azafaros's board of directors, alongside BGV managing partner Edward van Wezel and BioMedPartners general partner Andreas Wallnöfer. Vanessa King joins the board as an independent non-executive member.

The fresh capital will be used to expand the company's executive team and strengthen the organisation.

Company
Azafaros was established in 2018 to translate innovative science from Leiden University and Amsterdam University Medical Center into disease-modifying treatment modalities for rare genetic metabolic disorders. The company is headquartered in Leiden.

People
Azafaros – Olivier Morand (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Venture
• Netherlands